Optinose Narrows FY24 XHANCE Net Revenue Guidance From $85M - $95M To $85M - $90M And Increases Expected Average Net Revenue Per Prescription Guidance To Be At Least $250
Portfolio Pulse from Benzinga Newsdesk
Optinose has revised its FY24 net revenue guidance for XHANCE, narrowing the range from $85M-$95M to $85M-$90M. Additionally, the company has increased its expected average net revenue per prescription to at least $250.
August 08, 2024 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Optinose has adjusted its FY24 net revenue guidance for XHANCE, narrowing the range to $85M-$90M and increasing the expected average net revenue per prescription to at least $250.
The narrowing of the revenue guidance range suggests a more precise forecast, which can be seen as a positive sign of stability. Additionally, the increase in expected average net revenue per prescription indicates improved profitability per unit, which is likely to be viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100